Gaudium IVF and Women Health Limited has finalized its initial public offering (IPO) parameters, setting a price band of Rs 75 to Rs 79 per share. The company seeks to raise Rs 165 crore, a move that values the fertility specialist at approximately Rs 575 crore. The bidding process for the public issue is scheduled to open on February 20 and will conclude on February 24. Retail investors can participate with a minimum lot size of 189 shares, requiring an investment of Rs 14,931 at the upper price cap. Shares are expected to be credited to demat accounts by February 26, with the official listing on the BSE and NSE set for February 27. The offering is structured as a combination of a fresh issue worth Rs 90 crore and an offer for sale (OFS) of Rs 75 crore by the promoter. Out of the fresh proceeds, the company has earmarked Rs 50 crore to establish 19 new IVF centers across India. Another Rs 20 crore is designated for the repayment or prepayment of existing debt, with the remainder supporting general corporate expansion. Gaudium IVF has demonstrated robust financial momentum leading up to its market debut. For the fiscal year ending March 31, 2025, the company reported operational revenue of Rs 70.72 crore, marking a 32% increase from the previous year. Profit after tax reached Rs 19.13 crore for the same period. For the first half of the current fiscal year (H1FY26), the firm recorded a total income of Rs 49.75 crore and a profit of Rs 12.51 crore. The company currently operates a hub-and-spoke model with 7 primary centers and 28 strategic alliance locations across 30 cities. This infrastructure positions Gaudium to capitalize on a rapidly expanding domestic fertility market. The Indian In-Vitro Fertilization (IVF) sector is projected to grow at a CAGR of approximately 13%, reaching an estimated valuation of USD 4.54 billion by 2034. This IPO represents a landmark event as Gaudium becomes the first dedicated fertility services provider to list on Indian exchanges. The move follows a broader trend of investor interest in the Assisted Reproductive Technology (ART) sector, driven by rising infertility rates, delayed parenthood, and increased medical awareness. While the grey market premium (GMP) currently remains muted at Rs 0, the subscription phase will serve as a key sentiment indicator for the healthcare services sector. Following this debut, other major players like Indira IVF are expected to monitor performance closely as they consider their own public listings.